Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2Phase NA 1Phase 2 1

Status

Completed 6Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Thoracic 4Tumor-Agnostic 1Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 21Neurofibromatosis 1 19Melanoma 11Neurofibroma, Plexiform 10Lung Neoplasms 8Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Breast Neoplasms 7Solid Tumours 5Pancreatic Neoplasms 5Carcinoma, Hepatocellular 4Uveal Melanoma 3Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Rectal Neoplasms 3Neurofibrosarcoma 3Gallbladder Neoplasms 3Colonic Neoplasms 3Biliary Tract Neoplasms 3Thyroid Cancer, Papillary 2Sarcoma 2Bile Duct Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Renal Insufficiency 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × AZD 6244 × Clear all
NCT01933932 2025-11-19

SELECT-1

AstraZeneca

Phase 3 Active not recruiting
510 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT01750281 2023-10-24

SELECT-2

AstraZeneca

Phase 2 Completed
212 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03745989 2023-07-27

MK-8353-014

Merck Sharp & Dohme LLC

Phase 1 Completed
30 enrolled 19 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT01809210 2018-03-13

SELECT-3

AstraZeneca

Phase 1 Completed
55 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00970359 2017-04-12

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

Memorial Sloan Kettering Cancer Center

Phase NA Completed
24 enrolled 8 charts
Head & Neck

Neoplasm Metastasis, Thyroid Diseases, Thyroid Neoplasms

NCT01974752 2017-01-05

SUMIT

AstraZeneca

Phase 3 Completed
152 enrolled 14 charts
Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT01605916 2016-10-21

Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer

AstraZeneca

Phase 1 Completed
33 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡